Prostate-Specific Antigen Nadir and Cancer-Specific Mortality Following Hormonal Therapy for Prostate-Specific Antigen Failure
- 20 September 2005
- journal article
- genitourinary cancer
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (27), 6556-6560
- https://doi.org/10.1200/jco.2005.20.966
Abstract
Purpose: For men receiving androgen-suppression therapy (AST) for a rising postoperative or postradiation prostate-specific antigen (PSA), we evaluated whether a PSA nadir of more than 0.2 ng/mL was significantly associated with prostate cancer–specific mortality (PCSM). Patients and Methods: The study cohort comprised 747 men with rising PSA and negative bone scan after surgery (n = 486) or radiation therapy (n = 261) who were treated with AST. Cox regression was used to evaluate whether a significant association existed between the PSA nadir level after 8 months of AST and the time to PCSM, controlling for treatment and known prognostic factors. Results: The post-AST PSA nadir (pCox < .0001), the pre-AST PSA doubling time (DT) (pCox = .002), PSA level (P = .0001), and Gleason eight to 10 cancers (pCox = .01) were significantly associated with time to PCSM. The adjusted hazard ratio for PCSM was 20 (95% CI, 7 to 61; pCox < .0001), for men with a PSA nadir of more than 0.2 ng/mL as compared with all others. A PSA DT of less than 3 months was observed in 30% (224 of 747) of the study cohort. Of the 28 observed prostate cancer deaths, 21 (75%) occurred in men whose PSA nadir was more than 0.2 ng/mL and who had a PSA DT of less than 3 months. Conclusion: A PSA nadir of more than 0.2 ng/mL after 8 months of AST given for postoperative or postradiation PSA failure is significantly associated with PCSM and is clinically significant because it accounted for 75% of the cancer deaths observed in this study.Keywords
This publication has 14 references indexed in Scilit:
- THE NATURAL HISTORY OF ANDROGEN INDEPENDENT PROSTATE CANCERJournal of Urology, 2004
- 10-Year Outcome for Men With Localized Prostate Cancer Treated With External Radiation Therapy:: Results of a Cohort StudyJournal of Urology, 2004
- Surrogate End Point for Prostate Cancer-Specific Mortality After Radical Prostatectomy or Radiation TherapyJNCI Journal of the National Cancer Institute, 2003
- Biochemical (Prostate Specific Antigen) Recurrence Probability Following Radical Prostatectomy for Clinically Localized Prostate CancerJournal of Urology, 2003
- Prognostic Significance of The Nadir Prostate Specific Antigen Level After Hormone Therapy for Prostate CancerJournal of Urology, 2002
- ProstatePublished by Springer Science and Business Media LLC ,2002
- Introduction to Department of Defense Center for Prostate Disease Research Multicenter National Prostate Cancer Database, and analysis of changes in the PSA-eraUrologic Oncology, 2001
- Natural History of Progression After PSA Elevation Following Radical ProstatectomyJama-Journal Of The American Medical Association, 1999
- Consensus statement: Guidelines for PSA following radiation therapyInternational Journal of Radiation Oncology*Biology*Physics, 1997
- The capsure database: a methodology for clinical practice and research in prostate cancerUrology, 1996